GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003133113 | Lung | AIS | positive regulation of cellular catabolic process | 89/1849 | 427/18723 | 6.12e-12 | 4.46e-09 | 89 |
GO:001605512 | Lung | AIS | Wnt signaling pathway | 91/1849 | 444/18723 | 9.38e-12 | 5.47e-09 | 91 |
GO:019873812 | Lung | AIS | cell-cell signaling by wnt | 91/1849 | 446/18723 | 1.22e-11 | 6.13e-09 | 91 |
GO:190336213 | Lung | AIS | regulation of cellular protein catabolic process | 62/1849 | 255/18723 | 1.37e-11 | 6.13e-09 | 62 |
GO:003011112 | Lung | AIS | regulation of Wnt signaling pathway | 70/1849 | 328/18723 | 3.81e-10 | 8.87e-08 | 70 |
GO:009719313 | Lung | AIS | intrinsic apoptotic signaling pathway | 63/1849 | 288/18723 | 1.02e-09 | 2.12e-07 | 63 |
GO:200005813 | Lung | AIS | regulation of ubiquitin-dependent protein catabolic process | 43/1849 | 164/18723 | 1.55e-09 | 2.91e-07 | 43 |
GO:190332013 | Lung | AIS | regulation of protein modification by small protein conjugation or removal | 55/1849 | 242/18723 | 2.75e-09 | 4.92e-07 | 55 |
GO:190336413 | Lung | AIS | positive regulation of cellular protein catabolic process | 41/1849 | 155/18723 | 2.79e-09 | 4.92e-07 | 41 |
GO:190305013 | Lung | AIS | regulation of proteolysis involved in cellular protein catabolic process | 51/1849 | 221/18723 | 5.97e-09 | 9.87e-07 | 51 |
GO:200123313 | Lung | AIS | regulation of apoptotic signaling pathway | 71/1849 | 356/18723 | 6.10e-09 | 9.87e-07 | 71 |
GO:004586213 | Lung | AIS | positive regulation of proteolysis | 73/1849 | 372/18723 | 7.68e-09 | 1.21e-06 | 73 |
GO:003164713 | Lung | AIS | regulation of protein stability | 62/1849 | 298/18723 | 1.06e-08 | 1.63e-06 | 62 |
GO:200006013 | Lung | AIS | positive regulation of ubiquitin-dependent protein catabolic process | 31/1849 | 107/18723 | 2.36e-08 | 3.12e-06 | 31 |
GO:004316113 | Lung | AIS | proteasome-mediated ubiquitin-dependent protein catabolic process | 77/1849 | 412/18723 | 2.74e-08 | 3.47e-06 | 77 |
GO:001049813 | Lung | AIS | proteasomal protein catabolic process | 87/1849 | 490/18723 | 4.15e-08 | 5.03e-06 | 87 |
GO:003139613 | Lung | AIS | regulation of protein ubiquitination | 46/1849 | 210/18723 | 1.71e-07 | 1.72e-05 | 46 |
GO:001657012 | Lung | AIS | histone modification | 81/1849 | 463/18723 | 2.30e-07 | 2.16e-05 | 81 |
GO:006082812 | Lung | AIS | regulation of canonical Wnt signaling pathway | 52/1849 | 253/18723 | 2.40e-07 | 2.22e-05 | 52 |
GO:000647012 | Lung | AIS | protein dephosphorylation | 56/1849 | 281/18723 | 2.47e-07 | 2.24e-05 | 56 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LRRK2 | SNV | Missense_Mutation | rs200688492 | c.25N>G | p.Cys9Gly | p.C9G | Q5S007 | protein_coding | tolerated_low_confidence(0.08) | benign(0.007) | TCGA-A2-A0SW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | PD |
LRRK2 | SNV | Missense_Mutation | novel | c.1307N>A | p.Leu436Gln | p.L436Q | Q5S007 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
LRRK2 | SNV | Missense_Mutation | | c.7522N>C | p.Glu2508Gln | p.E2508Q | Q5S007 | protein_coding | tolerated(0.53) | benign(0.012) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
LRRK2 | SNV | Missense_Mutation | novel | c.3266N>G | p.Asn1089Ser | p.N1089S | Q5S007 | protein_coding | tolerated(0.12) | possibly_damaging(0.71) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LRRK2 | SNV | Missense_Mutation | novel | c.4469N>T | p.Ala1490Val | p.A1490V | Q5S007 | protein_coding | tolerated(0.18) | possibly_damaging(0.602) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LRRK2 | SNV | Missense_Mutation | | c.5072N>C | p.Ile1691Thr | p.I1691T | Q5S007 | protein_coding | deleterious(0.04) | benign(0.215) | TCGA-AN-A0XO-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
LRRK2 | SNV | Missense_Mutation | | c.5312N>C | p.Arg1771Thr | p.R1771T | Q5S007 | protein_coding | tolerated(0.11) | benign(0.152) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LRRK2 | SNV | Missense_Mutation | novel | c.2515N>A | p.Leu839Ile | p.L839I | Q5S007 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-BH-A1FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
LRRK2 | SNV | Missense_Mutation | novel | c.7367N>C | p.Arg2456Thr | p.R2456T | Q5S007 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A28O-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
LRRK2 | SNV | Missense_Mutation | novel | c.6322N>A | p.Glu2108Lys | p.E2108K | Q5S007 | protein_coding | deleterious(0.03) | benign(0.27) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
120892 | LRRK2 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | AZD-1775 | ADAVOSERTIB | |
120892 | LRRK2 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | Pyridopyrimidinone derivative 2 | | |
120892 | LRRK2 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | 384403651 | | |
120892 | LRRK2 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | PMID28117607-Compound-21 | | |
120892 | LRRK2 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | Pyridopyrimidinone derivative 1 | | |
120892 | LRRK2 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | PALBOCICLIB | PALBOCICLIB | |
120892 | LRRK2 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | Aminopyridine derivative 2 | | |
120892 | LRRK2 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | 328083498 | | |
120892 | LRRK2 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | inhibitor | 328083494 | | |
120892 | LRRK2 | KINASE, SERINE THREONINE KINASE, ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE | | PHA-767491 | CHEMBL225519 | |